News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,036 Results
Type
Article (39026)
Company Profile (279)
Press Release (645731)
Section
Business (203862)
Career Advice (1988)
Deals (35362)
Drug Delivery (85)
Drug Development (80789)
Employer Resources (168)
FDA (16086)
Job Trends (14802)
News (344524)
Policy (32433)
Tag
Academia (2531)
Alliances (49063)
Alzheimer's disease (1225)
Approvals (16015)
Artificial intelligence (126)
Bankruptcy (352)
Best Places to Work (11528)
Biotechnology (200)
Breast cancer (116)
Cancer (1037)
Cardiovascular disease (91)
Career advice (1658)
Cell therapy (224)
Clinical research (64138)
Collaboration (366)
Compensation (191)
COVID-19 (2528)
C-suite (87)
Data (1064)
Diabetes (150)
Diagnostics (6131)
Earnings (84800)
Employer resources (146)
Events (109351)
Executive appointments (280)
FDA (16594)
Funding (330)
Gene therapy (172)
GLP-1 (572)
Government (4322)
Healthcare (18663)
Infectious disease (2610)
Inflammatory bowel disease (104)
Interviews (308)
IPO (16284)
Job creations (3623)
Job search strategy (1416)
Layoffs (412)
Legal (7851)
Lung cancer (165)
Manufacturing (170)
Medical device (13170)
Medtech (13175)
Mergers & acquisitions (19136)
Metabolic disorders (392)
Neuroscience (1482)
NextGen Class of 2024 (6499)
Non-profit (4463)
Northern California (1422)
Obesity (227)
Opinion (178)
Patents (98)
People (56207)
Phase I (19912)
Phase II (28247)
Phase III (21068)
Pipeline (445)
Postmarket research (2553)
Preclinical (8474)
Radiopharmaceuticals (234)
Rare diseases (206)
Real estate (5889)
Regulatory (21498)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1264)
Startups (3560)
United States (13044)
Vaccines (547)
Weight loss (166)
Date
Today (47)
Last 7 days (955)
Last 30 days (3454)
Last 365 days (35435)
2024 (32134)
2023 (40075)
2022 (51178)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29265)
2010 (27328)
Location
Africa (713)
Arizona (190)
Asia (37087)
Australia (6051)
California (3194)
Canada (1256)
China (240)
Colorado (142)
Connecticut (143)
Europe (79424)
Florida (439)
Georgia (112)
Illinois (336)
Indiana (191)
Kansas (96)
Maryland (569)
Massachusetts (2531)
Michigan (153)
Minnesota (268)
New Jersey (923)
New York (927)
North Carolina (689)
Northern California (1422)
Ohio (134)
Pennsylvania (818)
South America (1091)
Southern California (1264)
Texas (436)
Utah (88)
Washington State (353)
685,036 Results for "viacyte inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Vertex’s Viacyte Backs Out of CRISPR Diabetes Deal
Vertex still has an ongoing diabetes partnership with CRISPR, which gives it a non-exclusive license to the latter’s platform to develop a potential cure for type 1 diabetes.
January 9, 2024
·
2 min read
·
Tristan Manalac
Drug Development
CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.
March 10, 2023
·
3 min read
·
Jia Jie Chen
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Deals
Vertex Buys ViaCyte in Synergistic Deal Aimed at Curing Type 1 Diabetes
Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).
July 11, 2022
·
3 min read
·
Mark Terry
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Biotech Beach
ViaCyte to Participate in 2022 Advanced Technologies & Treatments for Diabetes Conference
Manasi Sinha Jaiman, M.D., M.P.H., who was recently appointed Chief Medical Officer at Viacyte Inc., will participate in the 15th International Conference on Advanced Technologies & Treatments for Diabetes’ (ATTD) session, Utility of PROs in Therapy Development for Type 1 Diabetes: Putting the End-User Upfront.
April 20, 2022
·
2 min read
Business
ViaCyte Appoints Marty Lorenzo as General Counsel
ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, announced the appointment of Marty Lorenzo as General Counsel.
November 30, 2021
·
2 min read
Press Releases
Boston Scientific Closes Acquisition of Axonics, Inc.
November 15, 2024
·
5 min read
Business
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
CRISPR Therapeutics and ViaCyte, Inc., today announced the first patient has been dosed in the Phase 1 clinical trial of VCTX210.
February 2, 2022
·
6 min read
Biotech Beach
ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit
ViaCyte, Inc. will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m. ET
October 20, 2021
·
1 min read
1 of 68,504
Next
